Work

Growth of pancreatic cancers with hemizygous chromosomal 17p loss of MYBBP1A can be preferentially targeted by PARP inhibitors

Year: 2020

Type: article

Abstract: hemizygous cells and impair cell growth, greater than its impact on wild-type cells. Our findings reveal how a cell essential gene with one allele lost in cancer cells can be preferentially susceptible to a specific molecular therapy, when compared to wild-type cells.

Source: Science Advances

DOI: 10.1126/sciadv.abc4517

Authors: Antony Hsieh, Jason R. Pitarresi, Jonathan Lerner, Greg Donahue, David Hsiehchen, Anil K. Rustgi, Kenneth Zaret

Institutions: University of Pennsylvania, The University of Texas Southwestern Medical Center, NewYork–Presbyterian Hospital, Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, Columbia University

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $4,500

Funders: Foundation for the National Institutes of Health, American Society of Clinical Oncology, National Cancer Institute, National Institute of Diabetes and Digestive and Kidney Diseases

Awards: Training Program in Gastrointestinal Sciences, Dissecting the oncogenic and pro-metastatic roles of PTHLH-mediated calcium signaling in pancreatic cancer, The role of p120ctn in PDAC epithelial-to-mesenchymal transition and metastasis, G8334114998

OpenAlex ID: W3107470451

FWCI: 0.183

Cites: 55

Cited by: 7

Related to: 10